Great Point Partners LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Great Point Partners LLC disclosed 39 US equity positions worth $408.3m in its Q1 2026 13F filing. The largest position was APGE at 7.7% of the reported book, followed by VOR and ZURA.
What did Great Point Partners LLC own in Q1 2026? Top 39 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 7.7% | $31.5m | 374,000 | – | |
| 2 | VOR VOR BIOPHARMA INC | Healthcare | 7.6% | $31.2m | 1,750,000 | – | |
| 3 | ZURA ZURA BIO LTD | Healthcare | 6.1% | $25.1m | 4,215,930 | – | |
| 4 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 6.0% | $24.3m | 1,750,000 | – | |
| 5 | NKTR NEKTAR THERAPEUTICS | Healthcare | 5.6% | $22.8m | 316,453 | – | |
| 6 | SOL-GEL TECHNOLOGIES LTD | 5.3% | $21.7m | 274,363 | – | ||
| 7 | ALMS ALUMIS INC | Healthcare | 4.6% | $18.9m | 856,061 | – | |
| 8 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 3.9% | $16.1m | 220,000 | – | |
| 9 | ANNX ANNEXON INC | Healthcare | 3.4% | $13.8m | 2,500,000 | – | |
| 10 | 4XC1 KALVISTA PHARMACEUTICALS INC | 3.3% | $13.6m | 675,000 | – | ||
| 11 | IMVT IMMUNOVANT INC | Healthcare | 3.3% | $13.6m | 545,625 | – | |
| 12 | JBIO JADE BIOSCIENCES INC | Healthcare | 3.3% | $13.6m | 964,462 | – | |
| 13 | CTNM CONTINEUM THERAPEUTICS INC | 2.6% | $10.5m | 800,198 | – | ||
| 14 | ZBIO ZENAS BIOPHARMA INC | 2.5% | $10.2m | 524,066 | – | ||
| 15 | NGNE NEUROGENE INC | 2.5% | $10.1m | 500,000 | – | ||
| 16 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.3% | $9.3m | 500,000 | – | |
| 17 | CLYM CLIMB BIO INC | Healthcare | 2.2% | $9.1m | 1,334,130 | – | |
| 18 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.2% | $9.0m | 183,330 | – | |
| 19 | EPRX EUPRAXIA PHARMACEUTICALS INC | 2.1% | $8.7m | 1,200,000 | – | ||
| 20 | VERA VERA THERAPEUTICS INC | Healthcare | 2.0% | $8.0m | 199,348 | – | |
| 21 | EVMN EVOMMUNE INC | 1.8% | $7.5m | 325,000 | – | ||
| 22 | LB PHARMACEUTICALS INC | 1.8% | $7.4m | 300,000 | – | ||
| 23 | CMPX COMPASS THERAPEUTICS INC | 1.7% | $7.1m | 1,350,000 | – | ||
| 24 | SCYX SCYNEXIS INC | 1.7% | $6.9m | 7,554,347 | – | ||
| 25 | PALI PALISADE BIO INC | Healthcare | 1.5% | $6.0m | 3,405,757 | – | |
| 26 | CNTX CONTEXT THERAPEUTICS INC | 1.4% | $5.9m | 2,238,496 | – | ||
| 27 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.4% | $5.9m | 842,106 | – | |
| 28 | SLN SILENCE THERAPEUTICS PLC | 1.3% | $5.4m | 1,020,489 | – | ||
| 29 | UNCY UNICYCIVE THERAPEUTICS INC | 1.3% | $5.2m | 796,558 | – | ||
| 30 | TENX TENAX THERAPEUTICS INC | 1.3% | $5.2m | 327,307 | – | ||
| 31 | PROMIS NEUROSCIENCES INC | 1.2% | $4.7m | 371,402 | – | ||
| 32 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.0% | $4.3m | 300,000 | – | |
| 33 | IMMX IMMIX BIOPHARMA INC | 0.8% | $3.2m | 350,000 | – | ||
| 34 | RZLT REZOLUTE INC | 0.7% | $2.9m | 951,809 | – | ||
| 35 | PHVS PHARVARIS N V | Healthcare | 0.6% | $2.3m | 82,800 | – | |
| 36 | HUMA HUMACYTE INC | 0.6% | $2.3m | 3,750,000 | – | ||
| 37 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.5% | $1.9m | 124,666 | – | |
| 38 | ALKS ALKERMES PLC | Healthcare | 0.4% | $1.8m | 50,000 | – | |
| 39 | IRD OPUS GENETICS INC | 0.4% | $1.5m | 324,340 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.